Cue fresh buyout talk: Amarin puts off sales-force decision

Amarin ($AMRN) once again pushed back its marketing timeline for the newly approved heart drug Vascepa. Rather than deciding whether to hire its own sales force as scheduled, it's putting off the decision till mid-December, when it has another chance to score new chemical entity (NCE) status from the FDA. Report